This column highlights the most interesting and useful biotechnology and pharmaceutical commentary from around the Web.
Link: Walgreen: How It Plans on Realizing $1 BIllion in Synergies
After a rough 2012, Walgreen
(NYSE:WAG) seems positioned to have a much improved 2013. [Regarding] Walgreen's acquisition of Alliance Boots...Early estimates predict the company to realize $100 to $150 million in combined synergies from the Alliance Boots partnership in 2013, and more than $1 billion by 2016.”
Link: Obamacare: Good Or Bad For Players Like Express Scripts?
Prescription plan administrator, Express Scripts
(NASDAQ:ESRX), might just be the most powerful force in the healthcare industry...But with Obamacare scheduled to go into full effect in 2014, should companies like Express Scripts be considered as value plays?...Express Scripts' revenue grew by an astounding 143.7% between 2011 and 2012...”
Link: An Insider Buys $300K Of CVS Caremark Corporation (CVS), Should Investors Follow?
"Last week, EVP & General Counsel, Thomas Moriarty bought 6,164 shares at $48.67, for an investment of $300,002. The purchase is more interesting in light of how close the price paid is to CVS's
(NYSE:CVS) 52-week, intraday high of $49.23."
Link: Abbott Recalls Synthroid Lots Over Container Defects
(NYSE:ABT) has recalled three lots of the thyroid-hormone replacement therapy Synthroid because some bottles had defects that could affect the stability of the tablets.”
Link: AstraZeneca to Pay $35 Million for Right to Ardelyx Kidney Drug
(NYSE:AZN) agreed to pay $35 million for the right to develop an experimental drug from Ardelyx to treat kidney-disease complications in Pascal Soriot’s first licensing agreement as AstraZeneca chief executive.”
Link: Eli Lilly & Co. Surged To A New High On Alzheimer's Study Results
"Eli Lilly & Co
. (NYSE:LLY) announced results from its Phase 3 EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease Monday afternoon. The results showed that patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo.”
Link: Anacor Says GSK Stops Development of Antibiotic
"Anacor Pharmaceuticals Inc
(NASDAQ:ANAC) said its partner GlaxoSmithKline Plc
(NYSE:GSK) stopped the development of their mid-stage experimental antibiotic to treat urinary tract and intra-abdominal infections.”
Link: Broker Darlings of the Dow: Johnson & Johnson Ranks As a Top 15 Analyst
“A study of analyst recommendations at the major brokerages shows that Johnson & Johnson
(NYSE:JNJ) is the No. 9 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel.”
Link: Pfizer Names Top Execs for Animal-Health Spinoff
(NYSE:PFE) has named nine executives to round out the leadership team for its planned animal-health spinoff, Zoetis...New York-based Pfizer plans an initial public offering for up to a 20% ownership stake in Zoetis, and may pursue the separation of the remaining 80% stake at a later date.”
Link: Rochester Medical Introduces Spirit™ Hydrocolloid Adhesive Sheath
“Rochester Medical Corporation
(NASDAQ:ROCM), the world's leading developer and manufacturer of silicone catheters for continence care, today announced its next generation of male external catheters with the launch of the Spirit™ Hydrocolloid Adhesive Sheath.”
News Today Digest
Link: Merck & Co., Inc. New Study on Type Two Diabetes
Pharmaceutical firm Merck & Co., Inc.
(NYSE:MRK) felt very honored and encouraged by the results, as it stated that it is about to move the treatment for initiating Phase III studies. The study on Type 2 diabetes included 685 patients who had inadequate blood-sugar control with diet and exercise. Merck & Co., Inc. now releases positive data for a new diabetes drug through its study results.”
The Markets Are Open
Link: VIVUS Inc Jumps On New Data
(NASDAQ:VVUS) shares soared 11% to $20.58 after Bloomberg Industries claims the prescription insurer payment rate for the company's Qsymia obesity drug rose 500 bps to 36% in its second week of availability. Vivus had previously suggested the initial coverage rate would be minimal.”
Link: EC Nod for Watson's Actavis Deal - Analyst Blog
“Watson Pharmaceuticals, Inc.
(NYSE:WPI) recently received the green signal from the European Commission (EC) for its proposed acquisition of privately-held generic pharma company Actavis.”
Link: Allergan Stock Rating Reaffirmed by Wells Fargo & Co.
“Wells Fargo & Co.
(NYSE:WFC) reaffirmed their outperform rating on shares of Allergan
(NYSE:AGN) in a research note released on Thursday morning....A number of other firms have also recently commented on AGN. Analysts at Credit Agricole upgraded shares of Allergan from an underperform rating to an outperform rating in a research note to investors on Monday, September 24.”
No positions in stocks mentioned.
The information on this website solely reflects the analysis of or opinion about the performance of securities and financial markets by the writers whose articles appear on the site. The views expressed by the writers are not necessarily the views of Minyanville Media, Inc. or members of its management. Nothing contained on the website is intended to constitute a recommendation or advice addressed to an individual investor or category of investors to purchase, sell or hold any security, or to take any action with respect to the prospective movement of the securities markets or to solicit the purchase or sale of any security. Any investment decisions must be made by the reader either individually or in consultation with his or her investment professional. Minyanville writers and staff may trade or hold positions in securities that are discussed in articles appearing on the website. Writers of articles are required to disclose whether they have a position in any stock or fund discussed in an article, but are not permitted to disclose the size or direction of the position. Nothing on this website is intended to solicit business of any kind for a writer's business or fund. Minyanville management and staff as well as contributing writers will not respond to emails or other communications requesting investment advice.